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Abstract
Childhood cancer patients treated with platinums often develop hearing loss and the degree
is classified according to different scales globally. Our objective was to compare concor-
dance between five well-known ototoxicity scales used for childhood cancer patients. Audio-
metric test results (n = 654) were evaluated longitudinally and graded according Brock,
Chang, International Society of Pediatric Oncology (SIOP) Boston, Muenster scales and the
U.S. National Cancer Institute Common Technology Criteria for Adverse Events (CTCAE)
version 4.03. Adverse effects of grade 2, 3 and 4 are considered to reflect a degree of hear-
ing loss sufficient to interfere with day-to-day communication (> = Chang grade 2a; > =
Muenster grade 2b). We term this “deleterious hearing loss”. A total number of 3,799 audio-
grams were evaluated. The prevalence of deleterious hearing loss according to the last
available audiogram of each patient was 59.3% (388/654) according to Muenster, 48.2%
(315/653) according to SIOP, 40.5% (265/652) according to Brock, 40.3% (263/652)
according to Chang, and 57.5% (300/522) according to CTCAEv4.03. Overall concordance
between the scales ranged from ĸ = 0.636 (Muenster vs. Chang) to ĸ = 0.975 (Brock vs.
Chang). Muenster detected hearing loss the earliest in time, followed by Chang, SIOP and
Brock. Generally good concordance between the scales was observed but there is still
diversity in definitions of functional outcomes, such as differences in distribution levels of
severity of hearing loss, and additional intermediate scales taking into account losses <40
dB as well. Regardless of the scale used, hearing function decreases over time and there-
fore, close monitoring of hearing function at baseline and with each cycle of platinum therapy
should be conducted.
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Introduction
Cisplatin and carboplatin are platinum compounds commonly used in the treatment of pediat-
ric malignancies. Ototoxicity, a common adverse effect of treatment with cisplatin, is initially
manifested as high frequency hearing loss commonly accompanied by tinnitus[1–4]. Hearing
impairment in children can enhance learning problems by influencing speech and language
development as children have difficulty understanding speech and sounds, especially in the
presence of ambient noise[5, 6]. The overall reported incidence of platinum-induced ototoxic-
ity in children approaches 60%[1, 7, 8] and is influenced by younger age, higher cumulative
cisplatin or cranial radiotherapy doses, and concomitant treatment with aminoglycosides and
furosemide[9–12]. Although carboplatin is considered less ototoxic than cisplatin, hearing
impairment can occur, especially with high doses[13–15]. Besides treatment and patient-
related factors, perception of the seriousness of ototoxicity is also influenced by the variability
in the criteria that are used to indicate degree of ototoxicity[16, 17]. Although all criteria used
to assign hearing loss grades do so on scales ranging from no hearing loss to severe hearing
loss, there is significant variability in the design and criteria included within the grading
systems.
Hearing status is usually measured by audiometry up to 8 kHz. For surveillance of hearing
loss, the 5-point U.S. National Cancer Institute Common Terminology Criteria for Adverse
Events (CTCAE) scale is the most commonly used classification to grade hearing loss (Table 1
and S1A Fig)[18]. Most clinicians are familiar with the interpretation of this grading system.
CTCAE grading is designed to identify adverse events that require clinical action, and is
aligned with the Medical Dictionary for Regulatory Activities (medDRA) to assign grades
based on expected severity of impact on physical functioning and daily living activities.
The Brock grading system is a 5-point scale and was specifically designed for pediatric
patients treated with cisplatin. This system is used to grade hearing loss progression from high
to lower frequencies, taking into account the typical cisplatin-induced configuration of high
frequency loss (Table 1 and S1B Fig)[19]. Hearing loss is classified according to the frequency
range where hearing thresholds exceed 40 dB. It is important to acknowledge that hearing
losses up to 40 dB at any frequency are not considered by Brock criteria and therefore, a Brock
grade 0 does not imply normal hearing status.
A modification of the Brock scale resulted in the more clinically-sensitive Chang criteria
that correlated with the expected course of treatment-induced ototoxicity in clinical trials
(Table 1 and S1C Fig)[20]. This scale classifies the loss based on a 7-point scale and accounts
for any hearing loss less than 40 dB at any frequency, thereby resulting in a greater clinical sen-
sitivity. This scale also includes sub-scales (grade 1a, 1b, 2a and 2b) to capture hearing thresh-
olds in the mild loss range of 20 to 40 dB at all frequencies.
The 8-point Muenster scale is based on the World Health Organization classification and
includes several subgroups (grade 2a, 2b, 2c, 3a, 3b and 3c)[21]. This grading system was
designed for early detection of hearing loss (Table 1 and S1D Fig).
More recently, the International Society of Pediatric Oncology (SIOP) Boston classification
was released through international consensus to report hearing outcomes in international clin-
ical trials for pediatric patients treated with platinum therapy (Table 1 and S1E Fig)[16]. This
is a 5-point scale, adopting components of the Brock, CTCAE, Chang and Muenster grading
scales and taking into account the functional outcome of a patient at the end of treatment.
Audiograms can be graded for degree of hearing loss according to the hearing status, based
on the audiogram alone. Alternatively, audiological datasets including additional information
such as immittance, otoacoustic emission, and speech audiometry findings as well as patient
history can be examined to determine the likelihood and extent of ototoxicity. The latter is
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important when an adverse drug effect is suspected and contribution to debilitation of addi-
tional etiologies must be eliminated. The objectives of this study are to summarize the baseline
characteristics of a large cohort of pediatric childhood cancer patients treated with platinum
compounds, and to compare five grading systems within this cohort.
Patients and methods
The analysis of the anonymized Canadian cohort was approved by the ethics committees of
the University of British Columbia and British Columbia’s Children’s Hospital. The analysis of
the anonymized Dutch cohort was approved by the ethics committee of the Erasmus Medical
Center (MEC-2015-169).
Study population
Patients were recruited from the BC Children’s Hospital (Vancouver, Canada), Alberta Chil-
dren’s Hospital (Calgary, Canada), Stollery Children’s Hospital (Edmonton, Vancouver), Win-
nipeg Health Sciences Centre (Winnipeg, Canada), London Health Sciences Center (London,
Canada), Hospital for Sick Children (Toronto, Canada), Kingston General Hospital (Kingston,
Canada), Children’s Hospital of Eastern Ontario (Ottawa, Canada), Hoˆpital Saint-Justine
(Montreal, Canada), IWK Health Center (Halifax, Canada), McMaster Children’s Hospital
(Hamilton, Canada), and the Erasmus Medical Center—Sophia Children’s Hospital (Rotter-
dam, the Netherlands). Ethical approval was obtained from local research ethics boards. Serial
audiological data were collected from 729 patients who received platinum chemotherapy
between November 1981 and November 2016. Patients with previous hearing problems
(n = 1) or missing data were excluded (n = 74). A total number of 654 patients were included
Table 1. Ototoxicity classification systems.











�20 dB at 1, 2 and 4 kHz
No
Grade 1:
>20 dB at 8 kHz
Grade 1:
>10 dB at�2 kHz
Grade 1:
>20 dB at >4
kHz
Grade 1:
�40 dB at 8
kHz
Grade 1a:
�40 dB at 6–12 kHz
Grade 2a:
>20�40 dB at �4
kHz
Grade 1b:
>20 dB and <40 dB at 4
kHz
Grade 2:
>20 dB at�4 kHz
(if 6 kHz measured, use 6 kHz)
Grade 2b:
>40�60 dB at �4
kHz
Grade 2:
>20 dB at �4
kHz
Grade 2:
�40 dB at �4
kHz
Grade 2a:
�40 dB at�4 kHz
Yes
Grade 3:
>20 dB at�3 kHz (if 3 kHz not measured, use 2 kHz)
Grade 2c:
>60 dB at�4 kHz
Grade 3:
>20 dB at 2 or 3
kHz
Grade 3:
�40 dB at �2
kHz
Grade 2b:
>20 and <40 dB at 1, 2 or
3 kHz
Grade 4:
Audiological indication for cochlear implant:�50
dB at �1 kHz
Grade 3a:
>20�40 dB at <4
kHz
Grade 4:
>40 dB at �2
kHz
Grade 4:
�40 dB at �1
kHz
Grade 3:
�40 dB at�2 or 3 kHz
Grade 3b:
>40�60 dB at <4
kHz
Grade 4:
�40 dB at�1 kHz
Grade 3c:
>60 <80 dB at <4
kHz
Grade 4:
�80 dB at <4 kHz
https://doi.org/10.1371/journal.pone.0210646.t001
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and the total number of audiological evaluations was 3,799. Characteristics of the 654 patients
studied are listed in Table 2. Age at start treatment ranged between 0 and 18.8 years (median:
5.4 years) and age at recent evaluation ranged between 1.2 and 35.6 years (median: 12.6 years).
The majority of children were treated for germ cell tumor, neuroblastoma, osteosarcoma and
brain tumor. Forty-four patients were treated with carboplatin, 469 patients were treated with
cisplatin alone, and 141 were treated with cisplatin and additional carboplatin. Ninety-eight
(15%) patients received additional cranial radiotherapy.
Outcome measures and definitions of ototoxicity
Serial audiogram data was available from pure tone audiometry at frequencies of 0.5, 1, 2, 3, 4,
6, and 8 kHz. Testing was performed by the pediatric audiologists. For the first method, we
retrospectively graded 3,789 audiograms from Canadian and Rotterdam patients for overall
degree of sensorineural hearing loss according to the following grading systems:, the Muenster
[21], the SIOP[16], Brock[19] and Chang[20] grading scales (Table 1). In case of asymmetric
hearing loss, the worst hearing ear was used for analysis. For the second method, CTCAE grad-
ing was used to phenotype for ototoxicity for 522 Canadian patients based on their serial audi-
ological data sets including any available additional data such as immittance tests, otoacoustic
emissions, extended high frequency data and audiologist’s narrative in addition to the audio-
grams[18]. The CTCAE criteria specify baseline evaluations to calculate the threshold shifts.
Because absolute hearing threshold baseline data was not available for many of the children,
absolute threshold levels were used instead of changes from baseline. When 6 kHz data was
available, it was used to differentiate grade 1 from grade 2; that is, a patient would be assigned
“grade 2” if the hearing threshold was greater than 20 dB at 6 kHz and at all frequencies tested
above 6 kHz and the remainder of the audiologic dataset supported an ototoxic effect as the
Table 2. Baseline characteristics of included patients.





Age at start treatment, median years (n (%)) 5.4 (0.05–18.8)
Age at recent evaluation, median years (n (%)) 12.6 (1.2–35.6)
Carboplatin, n (%) 185 (28.3)
Cumulative cisplatin dose, mg/m2 (range) 400 (55–1600)
Cumulative carboplatin dose, mg/mg2 (range) 1700 (250–9436)
Cranial radiotherapy, n (%) 98 (18.8)
Diagnosis, n (%)
Brain tumor 113 (17.3)
Carcinoma 11 (1.7)




Other malignancies 9 (1.4)
Retinoblastoma 1 (0.2)
Rhabdomyosarcoma 21 (3.2)
Soft tissue sarcoma 2 (0.4)
https://doi.org/10.1371/journal.pone.0210646.t002
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most likely etiology. Further, in the definition of grade 4, “indication for cochlear implant and
speech-language services” was specified as “hearing threshold of greater than or equal to 50
dB at 1 kHz and frequencies above”. If middle ear pathology or conductive hearing loss was
present, audiological grading was based on bone conduction thresholds. If bone conduction
thresholds were not obtained and there was indication of middle ear pathology, the assessment
was categorized as not evaluable. Demographics, cancer diagnosis and treatment exposures
were extracted from the medical records.
For the CTCAEv4.03, Brock and SIOP Boston, children with deleterious hearing loss were
defined as those with grade 2 or greater. For Muenster, patients were classified as having dele-
terious hearing loss if the grade was 2b or greater. For Chang, children with deleterious hearing
loss were defined as those with grade 2a or greater. To compare the longitudinal data of audio-
metric testing, we displayed the results of different ototoxicity classification systems. Due to
the absence of standardized measuring timepoints after the start of treatment, adjacent mea-
surements were combined at predetermined points. The prevalence of deleterious hearing
loss was determined at the date of treatment discontinuation, one year after treatment discon-
tinuation and 10 years after treatment discontinuation. Descriptive statistics included median
and range for continuous variables, and frequencies including percentages for categorical
variables.
Statistical analysis
Two approaches were used to compare the different ototoxicity classification systems as the
CTCAEv4.03 criteria were applied only on the last available audiogram of each patient. For
the first analysis all available audiograms were compared and for the second analysis the oto-
toxicity scales of the last available audiogram of each patient were compared. statistics were
estimated and we consider a clinically meaningful ĸ to be at least 0.70. All analyses were per-
formed using SPSS 24.0 software (SPSS Inc., Chicago, IL, USA).
Results
Prevalence of hearing loss
Evaluation of the first post treatment audiogram showed that 282/549 patients (51.4%) had
deleterious hearing loss according to Muenster, 231/548 (42.2%) according to SIOP, 182/549
(33.2%) according to Brock and 188/548 (34.3%) according to Chang. Median time after the
end of platinum treatment was 0.3 years (range: 1 day–26.2 years). The prevalence of ototoxic-
ity one year after treatment discontinuation (median: 1.38 years; range: 1.1–2.0 years) was 43%
according to Brock and Chang, 56% according to Muenster and 49% according to SIOP. Ten
years after treatment discontinuation (range: 9.01–10.98), the prevalence of ototoxicity was
46% according to Brock and Chang, 61% according to Muenster and 54% according to SIOP
(Table 3).
There is debate about how much of a child’s high frequency ability can be damaged before
the hearing loss has serious complications. For our comparison purposes we consider deleteri-
ous hearing loss for children, to be at grade 2 and higher degree on CTCAE, Brock and SIOP,
grade 2b and higher on Muenster scale, and grade 2a and higher on Chang scale. As shown in
Fig 1 and Table 4, the prevalence of deleterious hearing loss according to the last available
audiogram was 57.5% (300/522) on CTCAEv4.03, 59.3% (388/654) on Muenster, 48.3% (316/
653) on SIOP Boston, 40.5% (265/652) on Brock, and 40.2% (263/652) on Chang. The median
time from end of cisplatin treatment to the last available evaluation was 4.5 years (range: -3–
29.2 years).
Comparison of ototoxicity grading scales
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Concordance among audiological scales
The concordance among Muenster and Chang criteria was lowest (ĸ: 0.665) and the concor-
dance among Chang and Brock criteria was highest (ĸ: 0.969, Table 5). Among the patients
with deleterious hearing loss according to Brock, 98.3% also met this definition according
to Muenster criteria and among the patients with deleterious hearing loss according to Muen-
ster, 69.7% also met this definition according to Brock grading. Muenster grading considers
patients to have deleterious hearing loss earlier than Brock. Among the patients with deleteri-
ous hearing loss according to Chang, 85.1% also have deleterious hearing loss according to
Brock criteria and among the patients with deleterious hearing loss according to Brock, 99.2%
also have deleterious hearing loss according to Chang.
When we compared the ototoxicity criteria of the most recent available audiograms, con-
cordance among Muenster and Chang was lowest (ĸ: 0.636) and concordance among Chang
and Brock was highest (ĸ: 0.975, Table 5). Among the patients with deleterious hearing loss
according to Brock, 99.6% also meet this definition according to Muenster criteria and among
the patients with deleterious hearing loss according to Muenster, 68.4% also met this criteria
according to Brock grading. Among the patients with deleterious hearing loss according to






















CTCAEv4.03 171 (32.8) 50 (9.6) 133 (25.5) 153 (29.3) 14 (2.7)
Muenster 129 (19.7) 186 (13.3) 52 (7.8) 89 (13.6) 97 (14.8) 55 (8.4) 69 (10.7) 33 (5) 45 (6.9)
SIOP 215 (32.9) 123 (18.8) 103 (15.8) 109 (16.7) 103 (15.8)
Brock 255 (39.1) 132 (20.2) 153 (23.5) 77 (11.8) 35 (5.4)
Chang 249 (38.2) 96 (14.7) 44 (6.7) 59 (9) 38 (5.8) 130 (19.9) 36 (5.5)
Abbreviations: CTCAE = U.S. National Cancer Institute Common Technology Criteria for Adverse Events, SIOP = International Society of Pediatric Oncology Boston
https://doi.org/10.1371/journal.pone.0210646.t003
Fig 1. Prevalence of deleterious hearing loss (A) based on CTCAEv4.03�grade 2, Muenster�grade 2b, SIOP�grade 2, Brock�grade 2 and
Chang�grade 2a, and ototoxicity grade distribution (B) according to the last available audiogram.
https://doi.org/10.1371/journal.pone.0210646.g001
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Chang, 85.5% also had deleterious hearing loss according to Brock criteria. Among the patients
with deleterious hearing loss according to Brock, 98.5% also had deleterious hearing loss
according to Chang.
For grade 2, Brock, Chang and Muenster are similar in coding (hearing loss above or equal
to 40 dB at 4 kHz and above, Table 1). Thirty-two percent of the audiograms assigned a Brock
grade 2 were graded as Chang grade 2a (277/868, ĸ = 0.417) and 40% of the audiograms (345/
868, ĸ = 0.180) were graded as Muenster grade 2b and 2c (S2 Fig). Of the 281 audiograms
assigned a Chang grade 2a hearing loss, 277 (99%) were graded by Brock as grade 2 as well
and 273 (97%) were graded as Muenster grade 2b and 2c (ĸ = 0.368). Thirty-six percent of the
audiograms assigned a Muenster grade 2b and 2c were graded as Brock grade 2 (345/959) and
29% of the audiograms (273/959) were assigned a Chang grade 2a.
Chang grade 2b and SIOP grade 3 are similar in coding as well. Of the 231 audiograms
assigned a Chang grade 2b, 211 (91%, ĸ = 0.407) were graded by SIOP grade 3, and of the 684
audiograms graded as SIOP grade 3, 211 (31%) were graded by Chang as grade 2b.
Table 4. The prevalence of deleterious hearing loss at stop treatment, 1 year after stop and 10 years after stop treatment.
Stop treatment 1 year after stop treatment 10 years after stop treatment
Median years (range) 0.25 (1 day–1 year) 1.38 (1.1–2.0) 10.04 (9.01–10.98)
Muenster 184/403 (46%) 150/268 (56%) 56/92 (61%)
SIOP 178/402 (44%) 130/268 (49%) 50/92 (54%)
Brock 152/402 (38%) 115/268 (43%) 42/92 (46%)
Chang 160/403 (40%) 116/268 (43%) 42/92 (46%)
https://doi.org/10.1371/journal.pone.0210646.t004
Table 5. Concordance among different ototoxicity criteria.
All audiograms
Grading Kappa (ĸ)
Muenster vs. Chang 0.665
Muenster vs. Brock 0.666
Muenster vs. SIOP 0.739
SIOP vs. Brock 0.840
SIOP vs. Chang 0.850
Brock vs. Chang 0.969
Last available audiogram
Grading Kappa (ĸ)
Muenster vs. Chang 0.636
Muenster vs. Brock 0.641
CTCAEv4.03 vs. Brock 0.681
CTCAEv4.03 vs. Chang 0.681
Muenster vs. SIOP 0.744
CTCAEv4.03 vs. SIOP 0.797
SIOP vs. Chang 0.845
SIOP vs. Brock 0.851
CTCAEv4.03 vs. Muenster 0.857
Brock vs. Chang 0.975
Abbreviations: CTCAE = U.S. National Cancer Institute Common Technology Criteria for Adverse Events,
SIOP = International Society of Pediatric Oncology Boston
https://doi.org/10.1371/journal.pone.0210646.t005
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For grade 4 hearing loss, Brock and Chang are similar in coding as well. Of the 183 audio-
grams assigned a Brock grade 4 hearing loss, 181 (98.9%, ĸ = 0.945) were graded by Chang
grade 4 as well, and of the 199 audiograms graded as Chang grade 4, 181 (91%) were graded by
Brock as grade 4 as well.
Detection of hearing loss over time
Figs 2–5 show the sequential audiometric measurements. When evaluating the time to detec-
tion of deleterious hearing loss, on average, Muenster detected hearing loss the earliest in
time, followed by Chang, Brock and SIOP. The overall trend of hearing function was similar
between the different grading scales: hearing function decreased over time, stabilized at long-
term follow-up but showed no recovery.
Discussion
Several grading scales have been developed for the purpose of describing hearing loss in pedi-
atric oncology patients. In this study, the application of five commonly used ototoxicity grad-
ing scales was compared in a large cohort of cisplatin treated childhood cancer patients,
namely: Brock, Chang, Muenster, SIOP Boston and CTCAEv4.03. The scales were applied to
3,799 audiograms of 654 platinum-treated pediatric patients and a generally good concordance
between the scales was observed.
Fig 2. Progression of hearing loss based on Muenster grade. The time after start cisplatin treatment in 654 patients is depicted on the x-axis and the
hearing loss grade is depicted on the y-axis. The dots represent the mean and the whiskers represent the standard error of the mean ototoxicity grade.
The dotted horizontal line depicts the cut-off for hearing loss yes/no.
https://doi.org/10.1371/journal.pone.0210646.g002
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The Brock scale is the oldest ototoxicity scale that was developed taking into account the
course of high to low frequency loss[19]. Platinum agents first affect hearing sensitivity for the
high frequency, that is high-pitched sounds and progressively affects the sound spectrum from
high to lower frequencies, that is lower pitches[1]. In our study, a high degree of concordance
was observed between Brock and Chang (ĸ = 0.975). The Chang scale[20] was developed as
a modified version of the Brock scale which could explain the high concordance. Although
Brock grade 2 and Chang grade 2a are similar in coding (hearing loss above or equal to 40 dB
at 4 kHz and above), a major difference in the number of patients with grade 2 hearing loss is
noted (Brock grade 2: 23.5% and Chang grade 2a: 9%). The reason for this discrepancy could
be the incorporation the sub-scales in the Chang scale to capture hearing thresholds in the
mild loss range of 20 to 40 dB at all frequencies. A similar number of patients having hearing
loss were identified with Brock grade 4 (5.4%) and Chang grade 4 (5.5%, hearing loss above 40
dB at 2 kHz and above).
The SIOP Boston scale, validated on international multicenter audiological data[16], com-
bined all elements of all previously published ototoxicity classification systems and was based
on modification of the pediatric functional hearing loss scale of Lewis et al.[22]. Our study
was in accordance with Bass et al.[23], showing a strong concordance between the Chang and
SIOP scales. The observed concordance between SIOP and the other ototoxicity scales in our
study was high as well.
Fig 3. Progression of hearing loss based on Brock grade. The time after start cisplatin treatment in 654 patients is depicted on the x-axis and the
hearing loss grade is depicted on the y-axis. The dots represent the mean and the whiskers represent the standard error of the mean ototoxicity grade.
The dotted horizontal line depicts the cut-off for hearing loss yes/no.
https://doi.org/10.1371/journal.pone.0210646.g003
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Detection of early stage hearing loss and early prediction for the need of hearing support
was the motivation for the Muenster scale[21]. This is in accordance with our study, showing
that the Muenster scale detected deleterious hearing loss the earliest in time. Unfortunately,
cochlear damage in the extended high frequencies and detection on formal testing is not
reported by any of these grading scales. However, the American Speech-Language and Hearing
Association (ASHA) definition of ototoxicity will capture ototoxicity in the extended high fre-
quencies and is widely used among audiologists to help inform physicians that an adverse
effect has occurred, well before the conventional frequency range is affected. Both baseline
and repeat testing are required to monitor deterioration[24]. Although the Muenster scale was
developed and validated using the Brock scale, concordance between the Muenster and Brock
scale was low (ĸ = 0.641) in our study. Concordance between Muenster and Chang (ĸ = 0.636)
was low as well, while Muenster and SIOP scales (ĸ = 0.744), and Muenster and CTCAEv4.03
(ĸ = 0.857) showed higher concordances.
The CTCAE requires baseline testing to assess changes of hearing function. Since actual
baseline thresholds were often not available, we assumed baseline of 0 dB hearing loss at all fre-
quencies, and used hearing threshold levels. Our study showed lower concordance between
CTCAE version 4.03 and the Brock scale (ĸ = 0.681) than the study by Knight et al. (ĸ = 0.88)
[8]. However, Knight et al. used version 3 of the CTCAE criteria and we have used adjusted
CTCAE version 4.03 criteria based on absolute thresholds.
Fig 4. Progression of hearing loss based on SIOP grade. The time after start cisplatin treatment in 654 patients is depicted on the x-axis and the
hearing loss grade is depicted on the y-axis. The dots represent the mean and the whiskers represent the standard error of the mean ototoxicity grade.
The dotted horizontal line depicts the cut-off for hearing loss yes/no.
https://doi.org/10.1371/journal.pone.0210646.g004
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Within one year after end of treatment, 38% (Brock�grade 2), 38% (Chang�grade 2a),
62% (CTCAEv4.03�grade 2), 44% (SIOP�grade 2) and 46% (Muenster�grade 2b) of
patients had deleterious hearing loss. It is notable that ototoxicity may be occurring before the
adverse drug effect is captured on a conventional audiogram which only tests up to 8000 Hz.
Auditory access to the richness of the sound environment is diminished as a child losses hear-
ing, first in the extended high frequency range, progressing into the conventional frequency
range critical for understanding speech and for developing speech production and full lan-
guage concepts[25]. Audiologists assess audiological needs for patients on an individual basis.
Children will have significantly difficulty understanding language in the presence of back-
ground noise once their hearing threshold is greater than 20 dB at 6000 Hz and above. Typi-
cally, once the hearing threshold is greater than 20 dB at 3000 Hz and above in at least one ear,
corresponding to SIOP grade 3, a hearing aid will be considered. Children who have hearing
loss at 4000 or 6000 Hz and above may struggle with understanding language over distance or
in the presence of background noise[5, 26]. In such cases hearing equipment involving remote
microphone technology (e.g. a frequency modulation (FM) system) may be helpful.
In order to detect high frequency hearing loss at an early stage, extended high frequencies
above 8 kHz should be measured. With high frequency audiometry, treatment protocols
could be modified, or otoprotective medication such as sodium thiosulfate or amifostine
could be administered[27, 28]. With early detection of ototoxic effects, aural rehabilitation
and counseling can be introduced at an early stage during treatment. Of the evaluated scales,
Fig 5. Progression of hearing loss based on Chang grade. The time after start cisplatin treatment in 654 patients is depicted on the x-axis and the
hearing loss grade is depicted on the y-axis. The dots represent the mean and the whiskers represent the standard error of the mean ototoxicity grade.
The dotted horizontal line depicts the cut-off for hearing loss yes/no.
https://doi.org/10.1371/journal.pone.0210646.g005
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the Chang scale is the only scale to incorporate extended high frequency audiometry. Knight
et al. demonstrated ototoxicity in 25% of cisplatin-treated pediatric patients who did not
have ototoxicity in the conventional frequency range (up to 8000 Hz)[1]. Unfortunately the
required equipment is not always available and is not part of standard practice[29]. In gen-
eral, which classification system to use will depend on the purpose of the monitoring. If the
purpose is to detect ototoxic change as early as possible during treatment, the Muenster clas-
sification is the most useful. Hence, on the basis of earliest time to detect hearing loss, and
high concordance with other grading scales, as well as including progressive losses into the
lower frequencies (0.25–1 kHz), we found a benefit for using the Muenster classification as
the most optimal grading system for predicting clinically relevant ototoxicity during plati-
num treatment. This is supported by a study in a small subset of platinum-treated children
by Lafay-Cousin et al. who described that, already after two courses of cisplatin in childhood
cancer patients, Muenster criteria had a higher sensitivity (67%) and specificity (87%) to pre-
dict the need for a hearing aid after end of treatment compared to Brock, Chang, CTCAE
and ASHA[30]. However, more studies are needed to find the optimal classification system
that has a high correlation between the grading outcome and the functional outcome that is
easy to apply and to understand.
A large sample size and audiological grading according to Brock, Chang, SIOP Boston and
Muenster scales all performed by one researcher are strengths of this study. Since the ototoxic-
ity grading systems limit grade definition to audiograms, although they may have reasonable
concordance, they may be too simplistic for accurate phenotyping of hearing function. It can
make a significant difference whether grading is based on audiogram alone or on audiological
datasets that allow more effective elimination of other contributing factors to the hearing loss.
By assessing a child’s overall hearing status, additional etiologies should be eliminated by tak-
ing into account as many factors as possible, as was the case for the CTCAEv4.03 criteria in
our study.
The lack of standardized time points relative to platinum dosing for audiometric testing
during and after treatment for pediatric cancer is not only a limitation that we have encoun-
tered in our study, but is a general limitation in pediatric oncology. Protocols are essential for
prospective monitoring of hearing function in childhood cancer patients receiving treatment.
Ideally, hearing status will be measured after each cycle of cisplatin, although the medical treat-
ment plan may not be alterable, adjustment to the hearing loss as it unfolds can be helped with
suitable audiological counselling.
In summary, we evaluated the concordance among five ototoxicity grading scales using
Kappa values in a large cohort of pediatric patients that were treated with platinum chemo-
therapy. The analysis was not used to determine the best grading scale, but to compare the dif-
ferences between them. Differences in concordances appeared to be related largely to differing
distribution levels of severity of hearing loss, with some scales taking into account losses below
40 dB. Therefore, the classification scales are not interchangeable. Nevertheless, it is important
to take into consideration that platinum-induced hearing loss, regardless which grading scale
used, can have significant complications for children[6, 10]. In both psychosocial and develop-
mental areas, difficulties can arise[5, 8, 31]. We observed that hearing function continues to
decline with time and stabilizes at some point. This is in accordance with previous studies,
showing that platinum concentrations are detectable in plasma up to 20 years after administra-
tion[32, 33]. At long-term follow-up in our study, no improvement of hearing function was
observed.
It is our obligation as pediatric oncology professionals to consider the functional implica-
tions of hearing loss on educational and psychosocial scale[8, 34] and therefore, close monitor-
ing of hearing function after starting cisplatin treatment needs to be conducted.
Comparison of ototoxicity grading scales
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